Open AccessAnti-IL-5 Agents for the Treatment of Idiopathic Chronic Eosinophilic Pneumonia: A Case Series
Author(s) -
Hiroki Tashiro,
Koichiro Takahashi,
Yuki Kurihara,
Hironori Sadamatsu,
Yuki Kuwahara,
Shinya Kimura,
Naoko SueokaAragane
Publication year - 2022
Publication title -
journal of asthma and allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.162
H-Index - 30
ISSN - 1178-6965
DOI - 10.2147/jaa.s343272
Subject(s) - medicine , corticosteroid , adverse effect , pneumonia , surgery
Idiopathic chronic eosinophilic pneumonia (ICEP) is a rare, chronic respiratory disease. Corticosteroid therapy is effective for ICEP, but relapse is frequent after its tapering, which leads to chronic use and corticosteroid-related adverse effects. Currently, biological agents targeting interleukin 5 (IL-5) are considered alternatives for treating ICEP patients with frequent relapse, but the detailed effects are not fully understood.